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Abstract 
Background: The gut microbiota (GM) has been proposed as one of the main determinants of colorectal surgery 
complications and theorized as the “missing factor” that could explain still poorly understood complications. Herein, 
we investigate this theory and report the current evidence on the role of the GM in colorectal surgery.
Methods: We first present the findings associating the role of the GM with the physiological response to surgery. 
Second, the change in GM composition during and after surgery and its association with colorectal surgery complica-
tions (ileus, adhesions, surgical-site infections, anastomotic leak, and diversion colitis) are reviewed. Finally, we present 
the findings linking GM science to the application of the enhanced recovery after surgery (ERAS) protocol, for the use 
of oral antibiotics with mechanical bowel preparation and for the administration of probiotics/synbiotics.
Results: According to preclinical and translational evidence, the GM is capable of influencing colorectal surgery 
outcomes. Clinical evidence supports the application of an ERAS protocol and the preoperative administration of 
multistrain probiotics/synbiotics. GM manipulation with oral antibiotics with mechanical bowel preparation still has 
uncertain benefits in right-sided colic resection but is very promising for left-sided colic resection.
Conclusions: The GM may be a determinant of colorectal surgery outcomes. There is an emerging need to imple-
ment translational research on the topic. Future clinical studies should clarify the composition of preoperative and 
postoperative GM and the impact of the GM on different colorectal surgery complications and should assess the 
validity of GM-targeted measures in effectively reducing complications for all colorectal surgery locations.
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Background
Colorectal surgery represents the standard treatment for 
colorectal cancer in the context of a multimodal treat-
ment that is administered according to the stage and 
localization of the disease [1–3]. Colorectal surgery is 
also the mainstay of treatment for diverticular disease 
[4], inflammatory bowel disease (IBD), mechanical bowel 
obstruction, some proctological disorders and acute 
conditions such as colic injury and ischemia [5]. The 
control of risk factors for complications after colorectal 
surgery has been actively pursued throughout the years. 
Many short- and long-term outcomes have been consid-
erably ameliorated by the standardization of the surgical 
procedures and centralization to high-volume hospitals 
[6, 7]. Nevertheless, a substantial number of patients 
undergoing colorectal surgery experience postopera-
tive morbidity, mainly in terms of postoperative ileus 
(POI) (10–30%), surgical-site infections (SSIs) (6.5–20%), 
anastomotic leak (AL) (2.7–20%) and re-admission (8.1–
11.8%) [8–13].
There are well-recognized risk factors for postopera-
tive complications, some of which are patient-related 
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and unmodifiable (i.e., age, pre-existing comorbidities). 
Moreover, surgical complications have been associ-
ated with inadequate antisepsis, defects in the surgical 
technique and/or an insufficient learning curve for the 
specific colorectal procedure [8, 14–17]. However, the 
occurrence of postoperative complications is not com-
pletely understood for all patients, as they occur even in 
patients with few risk factors [8, 18].
In recent years, a novel factor has been recognized 
among those involved in the physiology of the gastro-
intestinal tract and the entire organism. The intestinal 
microbial composition, or the gut microbiota (GM), 
is involved in the regulation of enterocyte wellness and 
gastrointestinal homeostasis. Additionally, gut micro-
bial dysbiosis has been proven to play a significant role 
in the onset of disorders such as obesity, IBD, autoim-
mune diseases, diabetes, predisposition to infections and 
cancer [19, 20]. Last, a biunivocal relation of microbiota 
between trauma and stress (including surgical stress) has 
been identified [18]. Recently, these discoveries led to a 
challenge of the traditional mindset on the risk factors for 
surgical complications, proposing the GM as one of the 
determinant factors for their occurrence [18].
A better understanding of the complex interaction 
among the GM, colorectal surgery and perioperative 
care could significantly improve patient management, 
allowing for the optimization of surgical outcomes. In 
this review, we approach the knowledge on the GM 
from a surgical point of view, and we synthesize the cur-
rent knowledge on the role of microbiota in colorectal 
surgery.
Methods
The review of the literature was conducted with the fol-
lowing method:
• A search was conducted on Pubmed for all articles 
published up to May, 2020 with the following terms 
associated to “colorectal surgery” OR “hemicolec-
tomy” OR “rectal resection” OR “colorectal cancer” 
OR “colorectal surgery complications” OR “surgery”: 
“microbiota” OR “microbiome”.
• The abstract was screened by two authors (AA and 
CP) and the articles selected from the abstract were 
evaluated in full text.
• After evaluation of the full text, the articles were 
included according to their pertinence in regards of 
the main topics of the article: physiologic response 
to surgical stress and healing after surgery, colorectal 
surgery complications, role of bowel preparation and 
role of probiotics/prebiotics.
• The reference list of the articles evaluated in full text 
was screened for any other relevant article and those 
articles were evaluated according to the same crite-
ria.
The GM and the microbiome: definition and physiology
The microbiota is defined as the totality of microorgan-
isms that colonize a specific setting in a specific period. 
The human microbiota is the combination of all micro-
organisms that live symbiotically with humans (bacteria, 
fungi, viruses, archaea and protozoans). Most of these 
microorganisms are concentrated in the gastrointesti-
nal tract and represent the GM. The GM is affected, in 
terms of composition and gene expression, by multiple 
environmental agents, including dietary factors, smok-
ing, medicinal agents, stress, exercise, age, hormones 
and geographic location [21]. All these factors contrib-
ute to GM fluctuations, which have been recorded even 
on a daily basis, even though the GM has also shown an 
intrinsic tendency to return to a stable baseline [22]. The 
GM also has wide interpersonal variability [23]. For these 
reasons, a general consensus on the composition and 
characteristics of a “normal microbiota” has not yet been 
reached [24].
Another main factor that limits the study of the GM 
is that only 50% of the organisms in the human gut are 
cultivable in  vitro [25]. Only in recent years, with the 
widespread use of techniques such as transcriptomics, 
proteomics and metabolomics, has a better understand-
ing of GM composition, gene expression and function 
been reached [23]. The main techniques in use are the 
sequencing of the bacterial 16S ribosomal RNA (rRNA) 
gene, which is present in all bacteria and archaea and 
contains nine highly variable regions, allowing the dif-
ferent species to be easily distinguished [23], and ran-
dom sequencing (shotgun metagenomic data), in which 
sequences are matched to those of known functional 
genes in databases, giving better insight into the func-
tional properties of the GM. These methods are expected 
to be integrated in future years with mRNA, protein and 
metabolite profiling, which will further investigate the 
functional properties of the sequenced genes [22].
The sequencing of the human gut microbiome has 
enabled the identification of resident species that are 
usually constant, even though their relative percent-
ages have wide variations among different individuals 
[22]. In a healthy individual, the GM is usually com-
posed of one archaean phylum (Euryarchaeota) and 
five main bacterial phyla: Bacteroidetes, Firmicutes, 
Actinobacteria, Proteobacteria (including Escherichia 
coli and Pseudomonas aeruginosa) and Verrucomi-
crobia [26]. Microorganisms that feed on unabsorbed 
and undigested nutrients are those that seem to have 
an advantage in terms of survival. Accordingly, a 
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significant effect of diet on the GM has also been iden-
tified. The Western diet, rich in sugars and animal 
fats and low in fiber, has been related to an increase 
in Bacteroides and a reduction in Firmicutes, while an 
increase in Firmicutes has been associated with a high-
fiber diet [26–28].
To obtain a better comprehension of how the human 
host and GM actively interact and how alterations in 
the GM can be related to different diseases, the role 
of in  vivo and translational research based on animal 
models has also been fundamental. The main strategies 
in use have been the manipulation of the host’s genetic 
background (gene knockouts); the manipulation of 
GM composition through controlled inoculation in 
germ-free (GF) or gnotobiotic mice; and ecosystem 
interventions, including dietary changes, antibiotic 
treatment and fecal transplantation. Through human 
GM inoculation into a GF mouse, it has been possible 
to obtain a reliable human GM model in which 100% 
of the phyla and 88% of the taxa were reproduced [29].
According to the results obtained with these meth-
ods, two types of GM have been distinguished by loca-
tion: the mucosal-associated microbiota (MAM) and 
the luminal microbiota (LM) [30]. In humans, the LM 
is currently the most analyzed due to the simplicity 
of fecal sample collection. By contrast, the MAM is 
usually sampled using bowel-tissue biopsies obtained 
through endoscopy. In the MAM, Bacteroidetes and 
Proteobacteria are more represented, while Firmi-
cutes and Actinobacteria are more abundant in the LM 
[30]. Although the implications related to the different 
compositions of the MAM and the LM are still poorly 
understood, the MAM is more permanent and less 
susceptible to external factors, such as diet or stress 
[31], and each bacterium found in the LM is found in 
the MAM, while some bacteria are exclusively present 
in the MAM. These differences are attributed to differ-
ent antibacterial or mucosal factors, different oxygen 
tensions between the lumen and the mucosa and dif-
ferent access to nutrients [30]. The MAM is involved 
in the stimulation of mucus secretion and in the pro-
duction of short-chain fatty acids (SCFAs), such as 
acetate, butyrate and propionate, which have been 
regarded as regulators of gut physiology and mediators 
of the host immune system. Butyrate, mainly produced 
by the Firmicutes phylum, is involved in colonocyte 
metabolism, enhances intestinal barrier function and 
mucosal immunity, and has anti-inflammatory and 
anticancer activity [23, 32, 33]. Acetate, produced by 
anaerobes and in particular by Bifidobacterium, has 
been involved in defense mechanisms against exter-
nal agents, such as infection by enterohaemorrhagic 
Escherichia coli (EHEC) [34].
Physiological response to surgical stress and healing 
after colorectal surgery
Patients undergoing major surgery experience a com-
plex endocrine and metabolic response to surgical stress, 
known as the catabolic phase. This phase is directly 
proportional to the severity of trauma and consists of 
significant modifications in carbohydrate and protein 
metabolism, together with altered hormonal produc-
tion and responses [35]. Catabolic hormones, such as 
catecholamines and cortisol, increase, and the stimula-
tion of the renin-angiotensin axis leads to fluid reten-
tion. The production of inflammatory cytokines, such as 
IL-6, is also involved [36]. Catabolic modifications usu-
ally develop in peripheral tissues such as muscle, fat and 
skin and aim to increase the supply of energy and protein 
substrates to improve tissue damage repair and wound 
healing and to preserve critical organ function. The cata-
bolic phase usually reverts 3–8 days after surgery, and the 
patient transitions to an anabolic phase, characterized by 
a gradual restoration of body protein and fat stores and a 
final return to normal physiology [37]. The prolongation 
of the catabolic phase or its excessive magnitude may 
lead to counterproductive effects; therefore, most of the 
current perioperative strategies are targeted at minimiz-
ing these adverse effects [38].
Parallel to the systemic response to surgical stress, the 
process of wound healing occurs in all tissues that have 
been subjected to surgical trauma. This process has been 
principally studied in skin wounds, and it is divided into 
different phases. The first, associated with hemostasis, 
results in the activation of the inflammatory process. 
The subsequent inflammatory phase is characterized by 
neutrophil recruitment in an early phase, followed by 
monocyte and macrophage recruitment in a later phase. 
Macrophages are later involved in the resolution of the 
inflammatory process (through a switch from an M1 to 
an M2 phenotype) and in the initiation of the proliferative 
phase. This phase is characterized by the generation of 
new epithelial cells, by the migration/activation of fibro-
blasts and the consequent deposition of collagen, and 
through neoangiogenesis, all resulting in the formation 
of granulation tissue. The late phase is the remodeling or 
wound-maturation phase. During this phase, new, more 
resistant collagen is produced, and the scar is remod-
eled to acquire elasticity and resistance [39]. A scarless 
wound-repair process that usually occurs only in fetal 
healing [40] has been described in GF mice (mice with-
out commensal microbiota) by Canasso et  al. [40], who 
described that the wound-repair process of GF mice was 
faster than that of conventional mice and characterized 
by an earlier and greater presence of macrophages. When 
GF mice were recolonized with bacteria, the wound-
repair process became analogous to that of conventional 
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mice. In contrast, Okada et al. previously reported oppo-
site results, finding that the tensile strength of the surgi-
cal wound in the earlier stages of wound repair (3rd to 
8th postoperative day) was greater in conventional mice 
than in GF mice [41].
The anastomotic healing process has been modeled in 
the skin healing process, although it is less studied and 
still under investigation. The relative importance of the 
four layers of the bowel wall (mucosa, submucosa, mus-
cularis propria and serosa) has still not been quantified 
[42]. Similar to skin wound healing, in the anastomotic 
healing process, the inflammatory phase is character-
ized by the activity of platelets, neutrophils, macrophages 
and fibroblasts, with the release of numerous growth 
factors and the activation of proteases with an increase 
in collagenolysis. Indeed, 48  h after surgery, a colorec-
tal anastomosis loses 70% of its initial strength [43]. The 
following proliferative phase is characterized by smooth 
muscle cells and fibroblasts producing new collagen. 
During the remodeling phase, collagenase and other 
enzymes remodel the microscopic structure of the anas-
tomosis, increasing its elasticity and contractile capac-
ity [42–44]. The anastomotic healing process most likely 
begins at the level of the serosa, with the formation of a 
fibrotic cap that represents a matrix for fibroblasts [45]. 
The submucosal layer has been hypothesized to be the 
primary source of fibroblasts involved in the deposition 
of collagen [42]. The role of the mucosal layer has to be 
clarified, but it is probably related to the production of 
mucus, which may significantly contribute to anasto-
motic healing and to the regulation of bacterial transla-
tion [42]. Of note, previous studies detected no difference 
in the results between hand-sewn anastomoses, in which 
at least some of the distinctions between layers are often 
preserved, and stapled anastomoses, which involve all 
layers [46, 47]. AL has been attributed to derangement 
in one or more of the physiological processes involved 
(i.e., ischemia, excessive shift to a proinflammatory M1 
macrophage phenotype in the inflammatory phase, or 
excessive production of collagen-degrading enzymes in 
the remodeling phase) [48]. From a clinical point of view, 
there are well-known risk factors for AL. Some are modi-
fiable, such as obesity, nutritional status, preoperative 
bowel cleaning, preoperative anemia and intraoperative 
blood loss, whereas others, such as age, sex, comorbidi-
ties and radiochemotherapy, are unmodifiable [49, 50]. 
Of note, some of these factors have themselves been 
related to changes in microbiota composition [51].
How does colorectal surgery affect the GM?
Several factors could be implicated in changes in the 
composition of the GM during and after colorectal sur-
gery, including the following:
– Stress and the alteration of homeostasis: Stress 
and the GM are related through the bidirectional 
microbiota-gut-brain (MGB) axis, in which stress 
can influence the composition of the microbiota, 
and the microbiota can influence the host response 
to stress through immune, endocrine and metabolic 
pathways. The MGB axis has been extensively stud-
ied in trauma as well as in stress-related pathologies 
(i.e., posttraumatic stress disorder) [52]. Stress has 
been deemed able to modify the composition of the 
microbiota, and it may also be able to increase intes-
tinal permeability and favor the translocation of GM 
microorganisms through corticotropin-mediated 
mechanisms [53]. In patients with major burns, 6 h 
after the injury, the GM undergoes important rear-
rangements, with a reduction in up to 90% of phyla 
such as Bacteroides and Firmicutes and a relative 
increase in Proteobacteria (Escherichia coli, Pseu-
domonas aeruginosa, Enterococcus faecalis) [54]. In 
critically ill patients, a direct correlation among a 
depletion in obligate anaerobes, an increase in patho-
genic facultative anaerobes and the occurrence of 
major complications has been detected [55]. Finally, 
as demonstrated in a rat model, the MAM composi-
tion shifts after colectomy, with a significant increase 
in Enterococcus, Escherichia and/or Shigella spp. [56]. 
It is still unclear, however, to what degree the altera-
tion of the MGB axis may be responsible for the 
detected shift in the GM in these situations.
– Exposure to oxygen: Many species in the GM are 
facultative anaerobes or obligate anaerobes. Expo-
sure to oxygen during colorectal surgery (i.e., during 
bowel section or anastomosis) could cause a signifi-
cant depletion of these species. In 2014, Shogan et al. 
demonstrated that the opening of the bowel caused a 
loss of “good” obligate anaerobes, such as some Bac-
teroides, and a gain of “bad” facultative anaerobes, 
such as Enterococcus, in a rat model. This change was 
detected in the MAM but not the LM [56].
– Tissue ischemia: Bowel and vascular sections may 
cause temporary or permanent ischemia of the 
neighboring gastrointestinal tract. Ischemia itself, or 
ischemia–reperfusion syndrome, can cause signifi-
cant changes in the GM. In 2012, Wang et al. created 
an ischemia–reperfusion model in rats after 30 min 
of colic ischemia. They identified a change in the 
GM 1 h after reperfusion that reached a peak at 6 h 
after reperfusion and then gradually recovered; this 
change consisted of an early increase in E. coli and 
Prevotella and a later increase in Lactobacillus, in line 
with reperfusion and epithelial healing [57].
– Type of reconstruction: Different types of surgical 
reconstruction may lead to various consequences, 
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such as a variation in the quality of food digestion 
and in the absorption of nutrients and vitamins. Food 
digestion and nutrient absorption have been related 
to the action of the GM [58], and it has been theo-
rized that alterations in the GM due to surgical inter-
vention and the type of bowel reconstruction may 
be partly responsible for malabsorption and/or mal-
digestion following certain surgical procedures (espe-
cially bariatric procedures) [18, 59].
– Chemo/radiotherapy: Patients undergoing colorec-
tal surgery may have been exposed to neoadjuvant 
or induction therapy before the surgical procedure 
[1–3]. Previous studies have detected specific GM 
changes associated with the administration of spe-
cific chemotherapeutic agents [60]. Radiotherapy 
also seems to have a significant impact on the GM, 
as detected in some murine and human studies [61, 
62]. Moreover, there is preliminary evidence that 
radiotherapy causes a phenotypic shift in certain bac-
terial species, increasing their virulence and tissue-
destructive capacity [63].
The current hypothesis developed by some authors is 
that behind the occurrence of surgical complications 
(especially infective complications) is an impairment in 
the physiological return to basal GM homeostasis due to 
one or more of these factors. This delay could favor an 
increase in pathogenic bacteria and in the virulence of 
the commensal species and could even lead to immune 
system compromise or collapse [18].
Surgical complications and the involvement of the GM
The most frequent complications after colorectal resec-
tion are POI, SSIs and AL. These complications have been 
regarded as the main causes of unplanned re-admission, 
as reported in a 2013 meta-analysis that related 33.4% of 
all re-admissions to bowel obstruction, 15.7% to SSIs and 
12.6% to intraabdominal abscesses [64]. Patients under-
going diverting stoma and the exclusion of the distal 
colon are also known to develop diversion colitis, which 
may favor functional and infective problems after stoma 
closure [65–68].
Postoperative ileus
POI is defined as an absence of intestinal motility fol-
lowing the surgical procedure. The absence of postop-
erative peristalsis is considered “normal” for up to 24 h in 
the small intestine, up to 48 h in the stomach and up to 
72  h in the large intestine. For this reason, POI is usu-
ally defined as an absence of intestinal function after the 
fifth postoperative day, accompanied by nausea and/or 
vomiting [69]. POI is reported in 10–30% of patients after 
abdominal surgery and is linked to an increased length 
of stay and an increased rate of reoperation [13, 70]. The 
occurrence of POI has been linked with different mecha-
nisms, such as inflammation, inhibitory neural reflexes 
and neurohumoral peptides [13]. The GM is involved as 
a direct modulator of gut synapses that impair gastro-
intestinal motility or as a possible activator of dendritic 
cells, macrophages and monocytes involved in the mech-
anisms of inflammation [71, 72]. Dendritic cells produce 
IL-12, which is able to activate pathways that lead to 
POI. Moreover, IL-12 stimulates IFNɣ production by T 
helper 1 (Th1) cells, leading to the production of iNOS 
and NO by local macrophages, which contribute to the 
inhibition of smooth cell contraction [72]. In their study, 
Pohl et  al. noted a substantial reduction in IL-12 and 
iNOS, implicated in POI, after the depletion of the GM 
with oral antibiotics (OABs). Notably, this reduction was 
maximal in the colon and moderate in the small intestine 
[72], possibly due to a different physiopathological mech-
anism between the inflammatory cells and the GM and 
the different locations, even though this consideration is 
highly hypothetical. Overall, there is still scarce evidence 
linking the role of the GM to POI, and further research is 
needed.
Postoperative adhesions
Postoperative adhesions are a frequent consequence of 
abdominal surgery, and they are reported in 63%–97% of 
patients after major abdominal procedures [73]. Postop-
erative adhesions are associated with obstructive compli-
cations that may occur in the immediate postoperative 
period or even months or years later. The incidence of 
small bowel obstruction due to peritoneal adhesions 
after abdominal surgery is 2.1%–4.6% [74, 75]. In the era 
of laparoscopy, the incidence of postoperative adhesions 
and the rate of re-admissions directly related to adhe-
sions have been significantly reduced after colorectal 
surgery [76, 77]. However, postoperative adhesions still 
represent a significant burden and a cause for increased 
costs [77].
Adhesions occur as a consequence of peritoneal irri-
tation due to surgical trauma or local infection, leading 
to a pathological healing mechanism that results in an 
imbalance between fibrin deposition and degradation. 
When this imbalance occurs, fibroblast recruitment, the 
production of the extracellular matrix (ECM), collagen 
deposition, and angiogenesis lead to the development of 
adhesions [73]. This is favored by inflammation, the pro-
duction of cytokines and oxidative stress. The role of mast 
cells and their serotonin release also seem to be promi-
nent [56, 78, 79]. Recently, most of these mechanisms 
have been linked to the role of the GM [56]. In 2001, 
Bothin et  al. compared the peritoneal adhesion process 
of GF rats, ex-GF rats and E. coli-monocontaminated 
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or Lactobacillus-monocontaminated rats. They demon-
strated that GF mice had a lower capacity to form perito-
neal adhesions. When their microbiome was restored, the 
adhesion-forming ability was restored as well. In particu-
lar, E. coli-monocontaminated rats were more capable 
of creating peritoneal adhesion than rats contaminated 
by Lactobacillus. The authors stressed the probable role 
of bacterial leakage or translocation through the sutures 
to justify these results, supported by the well-known 
appearance of most adhesions in the area of bowel anas-
tomosis [80]. Moreover, recent studies have consistently 
demonstrated that serotonin production is lower in GF 
mice and that it is probably mediated by SCFA produc-
tion [81, 82].
Surgical‑site Infections and Anastomotic Leak (Table 1)
SSIs are defined as infections that occur within 30  days 
after an operation, and they involve the skin and subcu-
taneous tissue of the incision (superficial incisional) and/
or the deep soft tissue of the incision (deep incisional) 
and/or any part of the anatomy (for example, organs 
and spaces) other than the incision that was opened or 
manipulated during an operation (organ/space) [83]. SSIs 
have been reported in up to 30% of patients after colo-
rectal surgery [84]. Incisional SSIs are the most frequent 
type of SSIs, described in 6.2%–21.6 of patients [85–87]. 
Many strategies have been applied to reduce the rate of 
incisional SSIs, including the administration of intrave-
nous antibiotics, careful intraoperative bowel manipula-
tion and the use of wound protectors. These strategies 
have proven effective, although there are still many inci-
sional SSIs that are not preventable [84] and a subset 
of patients with less controllable risk factors (patients 
who are immunocompromised or are diabetic, patients 
undergoing emergency surgery, especially those with 
bowel perforation where the surgical field is highly con-
taminated) [88, 89]. The most represented pathogens in 
incisional SSIs are actually bowel bacteria, such as E. coli, 
P. aeruginosa and Enterococcus spp. [90]; therefore, the 
role of GM manipulation is under the spotlight to pre-
vent this complication. Improved healing and outcomes 
have been correlated with increased bacterial diversity 
and an instability of the local microbiome composition 
[91]. Probiotics as Lb. plantarum have been related to 
beneficial local immunomodulatory effects and to inter-
ference with pathogen colonization by P. aeruginosa, S. 
aureus, and S. epidermidis [92–94]. Probiotics also exert 
an indirect beneficial effect on cutaneous health through 
effects on systemic immunity, enhanced nutrient absorp-
tion, and the modulation of the gut-brain-skin axis. The 
main mediator of the gut-brain-skin axis is the posterior 
hypophysis hormone oxytocin [95], the production of 
which is significantly increased by probiotics, resulting 
in increased wound healing capacity both in mice and in 
humans [96].
Deep/organ-space SSIs have a reported incidence of 
3.8%-11.5% after colorectal surgery [85–87]. The most 
frequent cause of organ/space SSIs, especially in rec-
tal cancer surgery, is AL [97], even though it has been 
stressed how some underestimation of the AL rate has 
been associated with the deep/organ-space SSI definition 
[98]. AL has an incidence of 2–20% after colorectal sur-
gery. Most ALs occur after low anterior rectal resection, 
especially when the anastomosis is performed < 7  cm 
from the anal margin [11, 49]. Some physiopathologi-
cal studies have assessed the role of the GM in favoring 
anastomotic healing. Physiological levels of reactive oxy-
gen species (ROS) promote epithelial proliferation and 
intestinal barrier functions [99], and human commensal 
Lactobacilli have been shown to induce ROS generation 
in intestinal epithelial cells [100]. Other studies demon-
strated that specific GM species promote the re-epitheli-
zation of the injured mucosa by stimulating enhanced 
proliferation of intestinal epithelial cells in the nearby 
crypts [101, 102]. Accordingly, previous investigations on 
GF mice have demonstrated a reduced rate of intestinal 
epithelial cell migration [95, 101]. In 1999, Okada et  al. 
compared the anastomotic bursting pressures of ileal and 
colic anastomoses performed in GF, ex-GF (conventional-
ized), conventional, Lactobacillus-monocontaminated or 
Escherichia-monocontaminated rats. They found higher 
anastomotic bursting pressures in conventionalized and 
conventional rats than in GF and monocontaminated rats 
[103]. One of the first studies suggesting a direct role of 
the GM in AL was carried out by Cohn and Rives in 1955. 
They performed colic anastomosis in dogs, creating a 
model for leakage through the systematic devasculariza-
tion of 5 cm of the perianastomotic bowel. Following this 
procedure, the dogs were re-fed. One group of dogs was 
intra- and postoperatively treated with topical and sys-
temic antibiotics (achromycin administered per os and at 
the anastomotic level through a small tube inserted dur-
ing surgery and intramuscular penicillin), while the other 
group was treated with saline solution. The anastomoses 
of dogs treated with antibiotics healed, and ischemia sub-
sided in 6/7 dogs, while AL caused by ischemia was uni-
formly fatal in 6/6 dogs treated with saline solution [104]. 
In 1994, Schardey et  al. focused on esophagoduodenal 
AL after total gastrectomy. They created three rat mod-
els, one experimentally inoculated with P. aeruginosa, 
one conventional model and one decontaminated by 
OABs, and the rates of AL were 95%, 80% and 6%, respec-
tively  [105]. Some of these preliminary studies suggested 
that diversity in the microbiota was key to preventing AL, 
while others suggested that the key might in fact be local 
decontamination, even though antibiotic administration 
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led to less diversity. This apparent paradox may be 
explained by the presence of disruptive species that are 
controlled either by decontamination or by microbial 
diversity that contains their excessive proliferation.
Following these preliminary findings, some studies 
focused on the composition of the GM in patients expe-
riencing AL. In 2016, van Praagh et al. conducted a pilot 
study to assess the composition of the GM at the anas-
tomosis level after rectal resection. They collected the 
"doughnuts" from the circular stapler used for anasto-
mosis and extracted the 16S rDNA from 15 doughnuts: 
8 from patients experiencing AL and 7 from patients 
with no AL. Patients who did not develop AL had higher 
microbial diversity, while patients who experienced AL 
had less microbial diversity and a greater representation 
of Lachnospiraceae, in particular of the mucin-degrad-
ing Ruminococci spp. [106]. These results were supple-
mented by the publication of an extended version of this 
analysis in 2019, which confirmed that AL was associated 
with low microbial diversity and with a high abundance 
of Bacteroidaceae and Lachnospiraceae (in particular 
Blautia obeum). In conclusion, the definition of protec-
tive and favorable preoperative GM “signatures” for AL 
was proposed [107]. In 2019, Palmisano et  al. studied 
the composition of the preoperative fecal microbiota 
in patients undergoing surgery for colorectal cancer. 
Patients with AL had a relative paucity of Faecalibacte-
rium prausnitzii and Barnesiella intestinihominis and a 
relative abundance of bacteria promoting dysbiosis, such 
as Acinetobacter Iwoffii, Hafnia alvei and Acinetobacter 
johnsonii [107].
Another concept investigated by some authors is the 
“phenotypic shift” of some bacterial species to a more 
virulent phenotype. In 2015, Shogan et  al. described 
results obtained in a murine model in which colon resec-
tion with a perianastomotic segmental devascularization 
of 2 cm was performed. Fifty percent of the rats subjected 
to devascularization developed AL. At the microbiologi-
cal assessment, the site of AL was colonized by bacteria 
with increased expression of collagenase activity. In par-
ticular, E. faecalis and Proteus mirabilis had the highest 
collagenase activity, and there were two types of E. fae-
calis, one with low collagenase activity (E1) and one with 
high collagenase activity (E2) [48]. E2 E. faecalis had 
different gene expression levels and showed a marked 
capacity to degrade collagen I and activate tissue MMP-
9. Moreover, when a series of rats undergoing colorectal 
anastomoses were experimentally inoculated by enema, 
this bacterium was able to induce AL associated with 
the depletion of intestinal collagen. In another model 
of colorectal anastomoses where topical and parenteral 
antibiotics were introduced together with the devascular-
ization of the anastomosis, the administration of topical 
antibiotics was capable of reducing the levels of MMP9 
and eliminating the E2 strain [48]. In 2012, Oliveira et al. 
demonstrated a similar phenotypic shift (P1/P2) for P. 
aeruginosa. They analyzed four groups of rats: in group 
1, the rats underwent colic resection with colic anasto-
mosis; in group 2, in addition to undergoing resection 
and anastomosis, the rats were inoculated with P. aerugi-
nosa at the level of the cecum; in group 3, rats were sub-
jected to radiotherapy before resection and anastomosis; 
and in group 4, rats underwent radiotherapy, resection, 
anastomosis and P. aeruginosa inoculation. In group 4, P. 
aeruginosa acquired a single-nucleotide polymorphism 
mutation leading to the codification of a truncated pro-
tein. This mutation was imputed to radiation. The novel 
P2 phenotype was associated with pyocyanin production, 
increased collagenase activity, and high motility and dis-
played destructive activity even against cultured intesti-
nal epithelial cells [63].
In conclusion, most of the recent studies identified 
low microbial diversity, the prevalence of Enterobacte-
riaceae and their virulence shift as the prevalent mecha-
nism associated with leakage. This specific phenotypic 
shift may be triggered by radiotherapy. According to 
this hypothesis, colorectal anastomoses, which are actu-
ally those with the greater reported risk of AL, are also 
those where preoperative radiotherapy is more frequently 
applied for the treatment of rectal cancer [8, 63].
Diversion colitis
During surgery, a loop ileostomy is created to divert the 
fecal content to protect the colorectal anastomosis and 
diminish the risk for AL in patients with high-risk anas-
tomoses (i.e., low colorectal anastomoses, anastomoses 
in patients who underwent preoperative chemoradiation) 
[108]. In patients with a diverting ileostomy, the residual 
colon is defunctionalized. The defunctionalization of 
the colon may cause the occurrence of diversion colitis, 
namely, the inflammation of excluded segments of the 
colon in patients who have undergone colostomy or ile-
ostomy and have no history of IBD [108]. The prevalence 
of diversion colitis is extremely high, as it reaches almost 
the entire population of patients with excluded colons if 
the phenomenon is followed prospectively, beginning 3 
to 36  months after ileostomy creation [109, 110]. Even 
if its prevalence accounts for almost 100% of patients, 
diversion colitis is symptomatic in only 30% of patients. 
Symptoms consist of abdominal discomfort, tenesmus, 
rectal bleeding and/or mucus discharge. Endoscopy 
shows mucosal erythema, edema, nodularity, erosions, 
and ulcerations [65, 66]. The causes of this condition are 
poorly clarified but are probably due to an imbalance in 
the colic microbiome and to the consequent decrease in 
the production of SCFAs. Indeed, an inverse correlation 
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between the presence of Bifidobacterium, which is one 
of the principal producers of SCFAs, and the severity of 
diversion colitis has been documented [67]. Other con-
sequences of the deficit of SCFAs are a possible increase 
in arteriolar resistance that leads to ischemia in the colon 
and a reduction in the production of mucin; both of these 
consequences may be related to the occurrence of diver-
sion colitis [111]. Colic inflammation is also thought to 
be related to the relative prevalence of nitrate-reducing 
bacteria (NO producers) [112]. Medical therapy for the 
treatment of diversion colitis consists of SCFAs and 
5-aminosalicylic acid (5-ASA) enemas, steroids or fiber 
irrigation [65, 66]. A recent trial demonstrated that pre-
liminary anterograde stimulation of the efferent limb of 
the ileostomy and of the diverted colon in patients under-
going ileostomy reversal had very promising results in 
terms of shortened postoperative stay [113]. Moreover, 
autologous fecal transplantation, which showed promis-
ing results in the treatment of pouchitis, has also been 
proposed for the treatment of patients not manageable 
with alternative medical or surgical therapy [114, 115].
Influence of perioperative management on microbiota: 
the role of ERAS protocols
Enhanced Recovery After Surgery (ERAS) protocols are 
a standardized and coordinated care pathway designed 
to improve the multidisciplinary management of surgi-
cal patients [36, 38, 116] and reduce postoperative com-
plications and hospital stay [117, 118]. ERAS protocols 
consist of various recommendations for perioperative 
management, including preoperative, intraoperative and 
postoperative measures. Preoperative measures include 
a preliminary phase, consisting of counseling and patient 
education on surgical complications, stoma handling, 
nutrition and bowel preparation. In the immediate pre-
operative phase, ERAS protocols recommend a clear 
liquid diet up to 2 h before general anesthesia, carbohy-
drate-rich beverage intake and the avoidance of mechani-
cal bowel preparation (MBP) [38, 119]. Intraoperatively, 
ERAS protocols regulate the modality of anesthesia, the 
use of pain control agents, antiemetic prophylaxis, intra-
operative fluid management and the surgical approach. 
Postoperatively, ERAS protocols are focused on early 
mobilization and feeding. The use of opioids during 
and after surgery is also highly discouraged due to the 
increased risks for POI and postoperative complications 
[120]. All these measures are in line with the principle 
of reducing surgical stress; therefore, the use of ERAS 
protocols has great theoretical potential to minimize 
changes in the GM [36]. Nevertheless, only one study 
so far has investigated the possible correlation between 
the application of ERAS measures and changes in GM 
composition. In 2016, Shakhsheer et al. investigated the 
role of morphine administration on the integrity of the 
intestinal anastomosis and on the composition of the GM 
in a murine model. They performed a 1-cm colic resec-
tion with rectosigmoid anastomosis. Postoperatively, rats 
had free access to water and food. The rats were divided 
into two groups: one with a subcutaneous pellet slowly 
releasing morphine and one releasing placebo. All rats 
were sacrificed, and the integrity of the anastomosis 
was assessed by the anastomotic healing score (AHS). 
An AHS of 0 meant normal healing of the anastomosis, 
and an AHS of 4 meant a perianastomotic abscess with 
evident leakage. Of the 30 placebo-treated rats, only 1 
had an AHS of 3, while all the others had an AHS of 0. 
By contrast, 48.39% of the morphine-treated rats had an 
AHS of 0, 22.58% of them had an AHS of 1–2, 19.35% of 
them had an AHS of 3 and 9.48% an AHS of 4. The com-
position of the microbiota in the two groups was evalu-
ated, highlighting how morphine-treated rats had an 
increase in P. aeruginosa and in the high-collagenase phe-
notype of E. faecalis at the anastomotic site. The authors 
also demonstrated how both endogenous and exogenous 
morphine could directly activate E. faecalis to produce 
collagenases and affect the chemoattractant and adhesive 
capacity of P. aeruginosa [121].
The role of MBP and OAB preparations (Tables 2, 3)
MBP has been a surgical dogma for more than a century. 
MBP was administered to patients undergoing elective 
colorectal surgery or other abdominal operations where 
entrance into the colonic lumen was anticipated as a pos-
sible event. This practice was based on the theoretical 
rationale that the mechanical removal of feces and asso-
ciated microbes would result in a lower morbidity rate, 
particularly in fewer SSIs and ALs [122, 123].
MBP had unclear benefits and possible disadvantages, 
including patient discomfort; fluid and electrolyte imbal-
ance; and alterations of the GM and of the colonic mucus 
layer, with possible increased bacterial translocation [18, 
124, 125]. The administration of MBP has been progres-
sively abandoned after the accumulation of results on its 
lack of efficacy in numerous randomized controlled tri-
als (RCTs) [126, 127], culminating in the publication of a 
2011 Cochrane systematic review and meta-analysis that 
confirmed the absence of benefits in surgical outcomes 
associated with this practice [128]. Moreover, MBP was 
reported to actually increase the risk for postoperative 
SSIs in another meta-analysis [129].
The role of intravenous antibiotic prophylaxis was 
assessed in the early 1980s by Baum et al., and this tech-
nique was extensively applied in the following years 
[130]. In 2014, a Cochrane review identified a 65% risk 
reduction in patients receiving intravenous prophy-
laxis (relative risk (RR) 0.34, 95% confidence interval 
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(CI) 0.28–0.41), p < 0.00001) [131], validating the role of 
intravenous prophylaxis, which is not currently being 
questioned. In recent years, based on the hypothesis of 
previous sporadic findings [132], it has been postulated 
that the association of MBP with selective decontami-
nation of the gastrointestinal tract through the admin-
istration of nonabsorbable OAB preparations could be 
beneficial based on the rationale that MBP would reduce 
the fecal bulk and improve OAB delivery to the bowel 
mucosa [132]. Two large retrospective studies based on 
data from the American College of Surgeons National 
Surgical Quality Improvement Program (ASC-NSQIP) 
reported a significant role of MBP + OABs in reducing 
SSIs and overall postoperative complications [133, 134], 
and the guidelines of major American surgeon societies 
have changed accordingly [135–137].
Recent high-quality meta-analyses have also addressed 
this topic. In 2018, Rollins et al. conducted a comprehen-
sive systematic review and meta-analysis of RCTs and 
observational cohort studies with the aim of comparing 
the association between colorectal surgery postopera-
tive outcomes and the use of OABs with or without MBP 
[138]. According to the availability of the studies for each 
comparison, this group detected a significantly reduced 
risk of SSIs with the use of MBP + OABs compared with 
the use of MBP alone, and this finding remained consist-
ent even when analyzing only the RCT results. No sig-
nificant difference in SSIs for the comparison the use of 
MBP + OABs vs the use of OABs alone was found, nei-
ther in the combined analysis nor in RCTs. A significant 
reduction in SSIs for patients undergoing MBP + OABs 
vs no preparation and patients receiving OABs alone vs 
no preparation was found only in cohort studies, as RCTs 
were not available. Regarding AL, a reduced risk of AL 
was detected for the use of MBP + OABs vs the use of 
MBP alone only in the combined analysis, but this result 
was not confirmed in RCTs. No significant difference 
was detected for the use of MBP + OABs vs the use of 
OABs either in the combined analysis or in RCTs, and a 
significant reduction in AL was documented for the use 
of MBP + OABs vs no preparation only in cohort stud-
ies, as RCTs were not available. Interestingly, a subgroup 
analysis conducted in patients undergoing open and 
laparoscopic procedures documented that in the com-
bined analysis, the benefit of the use of MBP + OABs vs 
the use of MBP was limited to open procedures. In 2018, 
Toh et al. [139] presented the results of a network meta-
analysis of RCTs focused on the impact of the different 
bowel preparation regimens on SSIs. Their final results 
demonstrated a significant risk reduction in total and 
incisional SSIs with the use of MBP + OABs vs the use of 
MBP and a tendency towards reduced organ/space SSIs. 
Moreover, they detected a possible advantage for the use 
of MBP + OABs vs the use of OABs alone in the total 
rate of SSIs, even though this advantage was less clear 
in the analysis for incisional SSIs (where no difference 
between the use of MBP + OABs and the use of OABs 
was detected) and for organ/space SSIs (where the use of 
OABs alone ranked better than the use of MBP + OABs). 
The authors reported some limitations of the study due 
to the heterogeneity of the included RCTs in terms of 
disease location, the paucity of RCTs directly compar-
ing the use of MBP + OAB vs no preparation and the use 
of OABs vs no preparation that permitted only indirect 
comparisons, and the paucity of RCTs reporting data on 
laparoscopic procedures.
In 2017, an international, multicenter, prospective 
audit was conducted by the European Society of Colo-
proctology Collaborating Group on patients undergoing 
left-sided resections only. This audit was focused on the 
association among MBP, OABs and AL [140]. Among 
3676 patients followed prospectively, the group of 618 
patients receiving preoperative MBP + OABs presented 
the lowest rate of AL (6.1%) when compared with patients 
receiving MBP (9.2%) and patients receiving no bowel 
preparation (8.7%). Patients undergoing MBP + OAB 
treatment had relatively favorable clinicopathologi-
cal characteristics (fewer cardiovascular comorbidities, 
lower body mass index, lower rate of active smoking). 
Nevertheless, the risk of AL was almost halved in this 
category (odds ratio (OR) 0.52, 0.030–0.092, p = 0.02) 
after assessment by multivariable regression.
The safety and feasibility of OAB administration have 
already been investigated in some retrospective prelimi-
nary studies [141]. In 2019, the results of the SELECT 
multicenter RCT, which investigated the role of OABs in 
reducing the leak rate of patients undergoing colorectal 
surgery, were published [142]. In this trial, all locations 
of colectomy were included, but MBP was administered 
only for left-sided and rectal resections. A standard-
ized ERAS protocol was applied for all patients. The 
results demonstrated a significant reduction in postop-
erative infectious complications in the OAB group (14.9 
vs 26.9%, OR 0.47, 95% CI 0.29–0.76 in the multivari-
able analysis). However, the reduction in postoperative 
infectious complications was not the primary outcome 
of the trial, which was stopped after an interim analysis 
because it failed to demonstrate the superiority of the use 
of OABs in reducing the rate of AL (6.1 vs 9.7%, OR 0.61 
95% CI, 0.30–1.22). The multicenter MOBILE RCT, also 
published in 2019, compared the use of MBP + OABs vs 
no bowel preparation to reduce the risk of SSIs. A peri-
operative ERAS protocol was applied, and all colorectal 
resections were included (rectal resections represented 
2.5% of the trial population). The results did not show any 
significant difference in regard to SSIs, AL or reoperation 
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rate between the two groups [143]. In 2020, the late 
report of an RCT conducted in 1999–2004 was published 
[144]. In this RCT, the use of MBP + OABs vs MBP was 
investigated in patients undergoing rectal surgery. This 
RCT was stopped at an interim analysis after the recruit-
ment of only 80 patients (vs the 280 patients initially 
planned) due to a statistically significant reduction in the 
risk of AL in patients receiving MBP + OABs (5% vs 20%, 
p = 0.0425). Finally, the results of ORALEV, a phase III 
multicenter RCT comparing the use of OABs vs no OABs 
in patients undergoing colic resection, were recently pub-
lished. This trial purposely excluded patients undergoing 
rectal resection. In the experimental arm, OAB therapy 
consisted of a one-day oral administration of ciprofloxa-
cin and metronidazole. SSIs were the primary outcome, 
and the number of SSIs was significantly reduced in the 
OAB arm (5% vs 11%, p = 0.013) [145]. However, this 
reduction was limited to superficial/deep SSIs, as the 
number of organ/space SSIs was similar (1.9% vs 2.6%). 
Following the results of this study, the authors planned 
a second trial, ORALEV 2 (NCT04161599), that focused 
on the comparison between the use of MBP + OABs and 
the use of OABs alone, with SSIs as a primary outcome.
In conclusion, there is promising evidence on the role 
of MBP + OABs in reducing SSIs, especially in left-sided 
and rectal resections, where the use of MBP is wide-
spread, and, therefore, this comparison of the use of 
MBP + OABs vs the use of MBP is more pertinent. Over-
all, OAB preparation, either in combination with MBP or 
alone, showed promising evidence in the prevention of 
postoperative complications after elective colorectal sur-
gery. The use of OABs alone seemed to reduce the inci-
dence of SSIs when compared with no preparation. For 
the comparison between the use of MBP + OABs vs the 
use of OABs alone or no preparation, more evidence is 
needed, especially in regards to right-sided resection, in 
which the risk of AL is lower, the use of MBP is not rou-
tinely applied, and the risk of SSIs has already been mini-
mized by the widespread use of laparoscopy [146].
The role of probiotics and synbiotics
In addition to the administration of topical antibiotics 
to reduce the number of pathogenic species in the GM, 
GM manipulation has also been attempted through the 
administration of probiotics, prebiotics and synbiotics, 
with the aim of obtaining a shift in the balance between 
nonpathogenic species and pathogenic species. Probi-
otics have been defined as “live microorganisms that, 
when administered in adequate amounts, confer a health 
benefit on the host” [147]. After surviving transit in the 
proximal gastrointestinal tract, the primary activity of 
probiotics occurs in the colon. By contrast, prebiotics 
have been defined as “nonviable food component that 
confer health benefit(s) on the host associated with mod-
ulation of the microbiota” [148]. Last, synbiotics have 
been defined as a combination of probiotics and prebi-
otics [149]. In previous studies, probiotics have shown 
numerous properties, including a strong anti-inflamma-
tory effect and the capability of antagonizing the over-
growth of pathogenic bacteria (P. aeruginosa, S. aureus, 
E. coli and others) [150–152]. The most well-known and 
utilized probiotics are those of Lactobacillus and Bifido-
bacterium spp. [149]. Most studies have evaluated the 
possible benefits of probiotics when administered in the 
perioperative setting, with mixed results. In particular, 
some perplexity has arisen because the beneficial effect 
of probiotics was not consistent in all patients [153]. 
Recently, many comprehensive systematic reviews and/or 
meta-analyses have investigated the association between 
the administration of probiotics and synbiotics and 
abdominal surgery outcomes [154–156]. These system-
atic reviews and/or meta-analyses found only a few stud-
ies that targeted the sole use of prebiotic; therefore, they 
focused on probiotics and synbiotics, including 34 RCTs, 
in their analysis. Most of the included studies used mul-
tistrain probiotics. The results showed that the admin-
istration of probiotics and synbiotics almost halved the 
relative risk for postoperative infectious complications 
(RR 0.56, 95% CI 0.46–0.69, p < 0.00001), with an even 
greater effect in the subgroup of patients receiving synbi-
otics (RR 0.46, 95% CI 0.33–0.66, p < 0.00001). A positive 
trend was found for an increased duration in the admin-
istration of probiotics and synbiotics and diminished 
postoperative infectious complications, but the difference 
did not reach statistical significance. In the subgroup of 
patients receiving synbiotics, the postoperative length of 
stay was significantly reduced. The role of the administra-
tion of probiotics and synbiotics in patients undergoing 
colorectal surgery was analyzed by Darbandi et al. [155]. 
In their systematic review, they identified 21 relevant 
clinical trials and summarized that patients treated with 
probiotics and synbiotics had fewer postoperative infec-
tious complications and SSIs and a shorter duration of 
hospital stay. The beneficial effects in terms of postopera-
tive infections were imputed to a positive stimulation of 
innate immunity by the supplements. Darbandi et al. also 
reported that probiotics and synbiotics led to a reduc-
tion in intestinal permeability and bacterial translocation 
and to a greater preservation of the ratio of Lactobacillus 
spp. to Bifidobacteria and Enterobacteriaceae spp. Last, 
probiotics and synbiotics led to a lower grade of severe 
postoperative diarrhea and an increased postcolectomy 
quality of life in all gastrointestinal domains as assessed 
by validated questionnaires. Liu et al. conducted another 
meta-analysis in a population of patients undergoing 
colorectal surgery, including 9 RCTs, and confirmed that 
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the use of multistrain probiotics was beneficial in reduc-
ing the total number of infections (OR = 0.30, 95% CI: 
0.15–0.61, p = 0.0009), including both SSIs (OR = 0.48, 
95% CI: 0.25–0.89, p = 0.02) and non-SSIs (OR = 0.36, 
95% CI: 0.23–0.56, p < 0.00001). However, the use of non-
multistrain probiotics did not reduce the number of total 
infections or SSIs [156].
No significant adverse effects for the administration 
of probiotics and synbiotics were documented in any of 
these reviews. Of note, probably due to the limitations 
of the included trials, these systematic reviews did not 
report on the eventual administration of MBP or OABs. 
In summary, the use of symbiotic and multistrain probi-
otics had a significant effect on reducing the incidence of 
postoperative infectious complications, the length of stay 
and gastrointestinal symptoms after abdominal surgery, 
particularly colorectal surgery.
Considerations for future research
Growing evidence supports the role of the GM as an 
influencer of colorectal surgery outcomes. To date, stud-
ies have been limited by difficulty in the isolation of the 
different GM species due to the scarce availability and 
increased cost associated with sequencing techniques 
and animal laboratories. Most of the in  vivo studies 
conducted so far have been performed on animal mod-
els, which has partially limited the clinical application 
of the findings. Indeed, contrary to manipulated murine 
species, in humans, there is nonnegligible interpersonal 
variability in the composition of the GM. A solution to 
the problem of interpersonal variability would be the 
development of specific “signatures” related to the dif-
ferent colorectal surgery outcomes. A useful strategy to 
further understand the GM could be the use of artificial 
intelligence (AI) strategies to process the large amount 
of genomic information and develop the “signatures” 
through machine-learning strategies. From a clinical 
point of view, it seems reasonable to conduct further 
studies that associate individual pathogen species or dif-
ferent GM compositions with the development of com-
plications and to systematically test the composition of 
preoperative and postoperative microbiota to identify 
shifts in its composition or virulent shifts in individual 
species. Other studies should assess the clinical relevance 
of the manipulation of the GM through different antibiot-
ics and synbiotics. All these findings should be weighted 
on the new use of minimally invasive techniques.
Conclusions
The role of the GM in outcomes following colorectal 
surgery is becoming increasingly apparent. There is an 
emerging need to implement translational research on 
the topic, to confirm the animal results in humans and 
to correctly assess the magnitude of influence of the GM 
and its contribution to the multifactorial occurrence of 
postoperative infective complications. Future studies 
should clarify the preoperative and postoperative compo-
sition of the GM and the impact of the GM on the dif-
ferent colorectal surgery complications and assess the 
validity of GM-targeted measures in effectively reducing 
these events. Current evidence promotes the application 
of ERAS protocols and of all measures aimed at reducing 
surgical stress. Current evidence also validates the preop-
erative administration of multistrain synbiotics and pro-
biotics. In regard to the direct manipulation of the GM 
with MBP ± OABs, this strategy is still under investiga-
tion in right-sided colic resection but is very promising 
for left-sided colic resection, where MBP and OABs seem 
capable of significantly reducing the occurrence of SSIs 
and, possibly, AL.
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